These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 21959118)

  • 1. Impact of albumin on drug delivery--new applications on the horizon.
    Elsadek B; Kratz F
    J Control Release; 2012 Jan; 157(1):4-28. PubMed ID: 21959118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of serum proteins on drug delivery.
    Kratz F; Elsadek B
    J Control Release; 2012 Jul; 161(2):429-45. PubMed ID: 22155554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin as a drug delivery and diagnostic tool and its market approved products.
    Sethi A; Sher M; Akram MR; Karim S; Khiljee S; Sajjad A; Shah SN; Murtaza G
    Acta Pol Pharm; 2013; 70(4):597-600. PubMed ID: 23923383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical update of using albumin as a drug vehicle - a commentary.
    Kratz F
    J Control Release; 2014 Sep; 190():331-6. PubMed ID: 24637463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
    Kouchakzadeh H; Safavi MS; Shojaosadati SA
    Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
    Fu Q; Sun J; Zhang W; Sui X; Yan Z; He Z
    Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):262-72. PubMed ID: 19538176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
    Foote M
    Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
    Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
    Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE
    Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems.
    Kratz F; Warnecke A
    J Control Release; 2012 Dec; 164(2):221-35. PubMed ID: 22705248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of pro-drug therapy in the treatment of cancer.
    Ferguson MJ; Ahmed FY; Cassidy J
    Drug Resist Updat; 2001 Aug; 4(4):225-32. PubMed ID: 11991677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel prodrugs: toward smarter delivery of anticancer agents.
    Skwarczynski M; Hayashi Y; Kiso Y
    J Med Chem; 2006 Dec; 49(25):7253-69. PubMed ID: 17149855
    [No Abstract]   [Full Text] [Related]  

  • 16. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Uniqueness of Albumin as a Carrier in Nanodrug Delivery.
    Spada A; Emami J; Tuszynski JA; Lavasanifar A
    Mol Pharm; 2021 May; 18(5):1862-1894. PubMed ID: 33787270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.